Medical Clinic IV-Department of Cardiology, Municipal Hospital Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Karlsruhe, Germany.
Medical Clinic IV-Department of Cardiology, Municipal Hospital Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Karlsruhe, Germany.
Am J Cardiol. 2020 Apr 15;125(8):1202-1208. doi: 10.1016/j.amjcard.2020.01.015. Epub 2020 Jan 28.
This study aimed to investigate the rate of severe structural valve deterioration (SVD) and long-term outcomes of patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). Propensity score matched analysis of patients who underwent TAVI (n = 216) and SAVR (n = 216) between 2008 and 2012. Long-term echocardiographic parameters and clinical outcomes were assessed after more than 6 years after TAVI/SAVR. Rate of severe SVD was 10.5% versus 4.5% in the TAVI and SAVR groups, respectively, but the difference was not statistically significant (hazard ratio [HR] 2.5; 95% confidence interval [CI] 0.7 to 8.3; p = 0.159). This was largely driven by higher rates of mean transprosthetic gradient ≥40 mm Hg (7.0 vs 3.4%; p = 0.327) and aortic regurgitation (4.7% vs 0%; p = 0.058). TAVI patients had lower survival rates at 6 years than SAVR patients (40.7% vs 59.6%, respectively, p <0.001, HR 2.15; 95% CI 1.45 to 3.20). Rate of cardiovascular events (14.4% TAVI vs 18.2% SAVR, HR 0.8; 95% CI 0.4 to 1.3; p = 0.347) and permanent pacemaker implantation (PPI; 16.0% TAVI vs 9.2% SAVR, p = 0.234) was similar between the 2 groups. In conclusion, incidence of moderate and severe SVD was not statistically different between TAVI and SAVR. Rate of moderate or severe aortic regurgitation was significantly higher in the TAVI group with predominant use of first-generation valves. Reintervention rate was low in both groups. Survival rate was lower after TAVI, probably because of higher frailty index, but incidence of cardiovascular events, PPI, and SVD was similar in both groups.
本研究旨在探讨 2008 年至 2012 年间接受经导管主动脉瓣植入术(TAVI)或外科主动脉瓣置换术(SAVR)治疗的严重症状性主动脉瓣狭窄患者的严重结构性瓣膜恶化(SVD)发生率和长期结局。对 216 例 TAVI 患者和 216 例 SAVR 患者进行倾向评分匹配分析。TAVI/SAVR 后 6 年以上评估长期超声心动图参数和临床结局。TAVI 组和 SAVR 组的严重 SVD 发生率分别为 10.5%和 4.5%,但差异无统计学意义(风险比[HR]2.5;95%置信区间[CI]0.7 至 8.3;p=0.159)。这主要是由于平均跨瓣压差≥40mmHg 的发生率较高(7.0%比 3.4%;p=0.327)和主动脉瓣反流(4.7%比 0%;p=0.058)。TAVI 组患者 6 年生存率低于 SAVR 组(分别为 40.7%和 59.6%,p<0.001,HR 2.15;95%CI 1.45 至 3.20)。心血管事件发生率(TAVI 组 14.4%,SAVR 组 18.2%,HR 0.8;95%CI 0.4 至 1.3;p=0.347)和永久起搏器植入率(TAVI 组 16.0%,SAVR 组 9.2%,p=0.234)在两组之间相似。总之,TAVI 和 SAVR 之间中度和重度 SVD 的发生率无统计学差异。第一代瓣膜主要用于 TAVI 组时,中重度主动脉瓣反流发生率显著升高。两组再介入率均较低。TAVI 后生存率较低,可能是由于虚弱指数较高,但两组心血管事件、PPI 和 SVD 的发生率相似。